Fundraising Fox
/Companies
Sign in

CimCure

Amsterdam, NL · Founded 2016 · 1 known investors

Find your way into CimCure

375 people in our graph can introduce you to the CimCure team.

Sign up to see every warm intro you have to CimCure

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the CimCure team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

CimCure develops active cancer vaccines that use its proprietary Immune-Boost (iBoost) technology to prompt the body to produce antibodies that attack and destroy the blood vessels feeding solid tumours, stopping cancer growth. Founded as a spin-off from the Angiogenesis Laboratory at Amsterdam UMC, the biotech company targets all types and stages of solid tumours.

BiotechHealthtechMedical Devices

Founders & leadership

CimCure was founded in 2016 by Arjan Griffioen.

AGArjan Griffioen
Arjan GriffioenCSOArjan Griffioen is a professor of experimental oncology at Amsterdam UMC specializing in tumor immunology and angiogenesis, and serves as Chief Scientific Officer of CimCure, a spin-off biotech company from his laboratory that develops cancer vaccines using proprietary technology targeting solid tumors.
DE
Diederik EngbersenCEOHe concurrently directs LURIS, the knowledge transfer office of Leiden University Medical Center. His earlier roles include CEO of AngioTarget BV, interim CEO of Pluriomics, CTO of FABPulous, Head of Marketing EMEA at Accelerate Diagnostics, and partner positions at Middenduin Life Sciences and Pharmatide Invest.

Investors · 1

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Dutch cancer vaccine biotech CimCure fetches €5M to shrink a tumor effectively — TFNtechfundingnews.com · Jun 2022Cancer vaccine biotech CimCure raises € 5 million in seed round investment led by Positron Venturesprnewswire.com · Jun 2022

Frequently asked questions

What does CimCure do?
CimCure develops active cancer vaccines that use its proprietary Immune-Boost (iBoost) technology to prompt the body to produce antibodies that attack and destroy the blood vessels feeding solid tumours, stopping cancer growth. Founded as a spin-off from the Angiogenesis Laboratory at Amsterdam UMC, the biotech company targets all types and stages of solid tumours.
Who founded CimCure?
CimCure was founded by Arjan Griffioen in 2016.
Who are CimCure's investors?
CimCure's investors include Positron Ventures.
Where is CimCure headquartered?
CimCure is headquartered in Amsterdam, NL.